Index Entries

Anshul Jain, Rachna Chaurasia, Narendra Singh Sengar, Mayank Singh, Sachin Mahor, and Sumit Narain
Scientific Reports
M.L.B. Medical College (India)

“Study included either asymptomatic COVID-19 patients (Group A) or severely ill patients requiring ICU admission (Group B)… The mean level of vitamin D (in ng/mL) was 27.89 ± 6.21 in Group A and 14.35 ± 5.79 in Group B, the difference was highly significant. The prevalence of vitamin D deficiency was 32.96% and 96.82% respectively in Group A and Group B…The fatality rate was high in vitamin D deficient (21% vs 3.1%). Vitamin D level is markedly low in severe COVID-19 patients. Inflammatory response is high in vitamin D deficient COVID-19 patients. This all translates into increased mortality in vitamin D deficient COVID-19 patients. As per the flexible approach in the current COVID-19 pandemic, authors recommend mass administration of vitamin D supplements to population at risk for COVID-19…

Conclusion: Vitamin D deficiency markedly increases the chance of having severe disease after infection with SARS-Cov-2. The intensity of inflammatory response is also higher in vitamin D deficient COVID-19 patients. This all translates to increased morbidity and mortality in COVID-19 patients who are deficient in vitamin D. Keeping the current COVID-19 pandemic in view, authors recommend administration of vitamin D supplements to population at risk for COVID-19.”

document
COVID-19,medical treatments,nutraceuticals,vitamin D